Advertisement

Considerations for general anaesthesia in Parkinson’s disease

Published:November 10, 2017DOI:https://doi.org/10.1016/j.jocn.2017.10.062

      Highlights

      • Patients with Parkinson’s disease have an increased risk of perioperative morbidity.
      • Awareness of anaesthetic risks and medication requirements may improve outcomes.
      • There is little evidence linking anaesthetic exposure to development of the disease.

      Abstract

      Parkinson’s disease is a common neurodegenerative disorder in the elderly which when present has a significant influence on surgical management. These patients necessitate additional perioperative and anaesthetic considerations across disease specific domains as well as in relation to the respiratory and cardiovascular systems. This brief review focuses on the factors which contribute to perioperative morbidity, including the use of medications that may exacerbate symptoms or adversely interact with treatments for Parkinson’s disease. Recommended dosing practices to reduce complications during hospitalisation are covered. In addition, recent concerns regarding anaesthetic exposure in early childhood as a risk factor for the development of Parkinson’s disease are discussed in light of data from animal models of anaesthetic neurotoxicity and epidemiological studies.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Barbeau A.
        The pathogenesis of Parkinson's disease: a new hypothesis.
        Can Med Assoc J. 1962; 87: 802-807
        • Hutchinson M.
        • Raff U.
        Structural changes of the substantia nigra in Parkinson’s disease as revealed by MR imaging.
        Am J Neuroradiol. 2000; 21: 697-701
        • Nicholson G.
        • Pereira A.C.
        • Hall G.M.
        Parkinson's disease and anaesthesia.
        Br J Anaesth. 2002; 89: 904-916
        • Martinez-Martin P.
        • Rodriguez-Blazquez C.
        • Kurtis M.M.
        • Chaudhuri K.R.
        • Group N.V.
        The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease.
        Mov Disord. 2011; 26: 399-406
        • de Lau L.M.
        • Breteler M.M.
        Epidemiology of Parkinson’s disease.
        LancetNeurol. 2006; 5: 525-535
      1. Deloitte Access Economics. Living with Parkinson's Disease: An updated economic analysis 2014 http://www.parkinsons.org.au/Documents/Living%20with%20Parkinsons%2027082015%20FINAL.pdf; 2015.

        • Mellick G.D.
        Why we need better nationwide measures of Parkinson’s disease incidence and prevalence in Australia.
        Aust Epidemiol. 2013; 20: 20-22
        • Guttmacher A.E.M.D.
        • Collins F.S.M.D.P.
        • Nussbaum R.L.M.D.
        • Ellis C.E.P.
        Alzheimer's disease and Parkinson's disease.
        N Engl J Med. 2003; 348: 1356-1364
        • Mueller M.C.
        • Juptner U.
        • Wuellner U.
        • Wirz S.
        • Turler A.
        • Hirner A.
        • Standop J.
        Parkinson's disease influences the perioperative risk profile in surgery.
        Langenbecks Arch Surg. 2009; 394: 511-515
        • Eventov I.
        • Moreno M.
        • Geller E.
        • Tardiman R.
        • Salama R.
        Hip fractures in patients with Parkinson's syndrome.
        J Trauma. 1983; 23: 98-101
        • Pepper P.V.
        • Goldstein M.K.
        Postoperative complications in Parkinson's disease.
        J Am Geriatr Soc. 1999; 47: 967-972
        • Kalenka A.
        • Hinkelbein J.
        Anaesthesia in patients with Parkinson’s disease.
        Anaesthesist. 2005; 54 (quiz 410-401): 401-409
        • Shaikh S.I.
        • Verma H.
        Parkinson’s disease and anaesthesia.
        Indian J Anaesth. 2011; 55: 228-234
        • Gerlach O.H.
        • Winogrodzka A.
        • Weber W.E.
        Clinical problems in the hospitalized Parkinson's disease patient: systematic review.
        Mov Disord. 2011; 26: 197-208
        • Christian C.M.
        • Waller J.L.
        • Moldenhauer C.C.
        Postoperative rigidity following fentanyl anesthesia.
        Anesthesiology. 1983; 58: 275-277
        • Krauss J.K.
        • Akeyson E.W.
        • Giam P.
        • Jankovic J.
        Propofol-induced dyskinesias in Parkinson's disease.
        Anesth Analg. 1996; 83: 420-422
        • Zesiewicz T.A.
        • Hauser R.A.
        • Freeman A.
        • Sullivan K.L.
        • Miller A.M.
        • Halim T.
        Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease.
        Clin Neuropharmacol. 2009; 32: 48-50
        • Zornberg G.L.
        • Bodkin J.A.
        • Cohen B.M.
        Severe adverse interaction between pethidine and selegiline.
        Lancet. 1991; 337: 246
        • Derry C.P.
        • Shah K.J.
        • Caie L.
        • Counsell C.E.
        Medication management in people with Parkinson's disease during surgical admissions.
        Postgrad Med J. 2010; 86: 334-337
        • Mason L.J.
        • Cojocaru T.T.
        • Cole D.J.
        Surgical intervention and anesthetic management of the patient with Parkinson's disease.
        Int Anesthesiol Clin. 1996; 34: 133-150
      2. Australian Bureau of Statistics. Australian Demographic Statistics 3101.0. ABS, Canberra http://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/801757AC98D5DE8FCA257F1D00142620/$File/31010_jun%202015.pdf; 2015.

        • Gerlach O.H.
        • Broen M.P.
        • van Domburg P.H.
        • Vermeij A.J.
        • Weber W.E.
        Deterioration of Parkinson's disease during hospitalization: survey of 684 patients.
        BMC Neurol. 2012; 12: 13
        • Neu H.C.
        • Connolly Jr., J.J.
        • Schwertley F.W.
        • Ladwig H.A.
        • Brody A.W.
        Obstructive respiratory dysfunction in parkinsonian patients.
        Am Rev Respir Dis. 1967; 95: 33-47
        • Ebihara S.
        • Saito H.
        • Kanda A.
        • Nakajoh M.
        • Takahashi H.
        • Arai H.
        • Sasaki H.
        Impaired efficacy of cough in patients with Parkinson disease.
        Chest. 2003; 124: 1009-1015
        • Hoehn M.M.
        • Yahr M.D.
        Parkinsonism: onset, progression and mortality.
        Neurology. 1967; 17: 427-442
        • Troche M.S.
        • Okun M.S.
        • Rosenbek J.C.
        • Musson N.
        • Fernandez H.H.
        • Rodriguez R.
        • Romrell J.
        • Pitts T.
        • Wheeler-Hegland K.M.
        • Sapienza C.M.
        Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial.
        Neurology. 2010; 75: 1912-1919
        • Backus W.W.
        • Ward R.R.
        • Vitkun S.A.
        • Fitzgerald D.
        • Askanazi J.
        Postextubation laryngeal spasm in an unanesthetized patient with Parkinson's disease.
        J Clin Anesth. 1991; 3: 314-316
        • Gdynia H.J.
        • Kassubek J.
        • Sperfeld A.D.
        Laryngospasm in neurological diseases.
        Neurocrit Care. 2006; 4: 163-167
        • Liu E.H.
        • Choy J.
        • Dhara S.S.
        Persistent perioperative laryngospasm in a patient with Parkinson’s disease.
        Can J Anaesth. 1998; 45 (495 495)
        • Hovestadt A.
        • Bogaard J.M.
        • Meerwaldt J.D.
        • van der Meche F.G.
        • Stigt J.
        Pulmonary function in Parkinson's disease.
        J Neurol Neurosurg Psychiatry. 1989; 52: 329-333
        • Tzelepis G.E.
        • McCool F.D.
        • Friedman J.H.
        • Hoppin F.G.
        Respiratory muscle dysfunction in Parkinson’s disease.
        Am Rev Respir Dis. 1988; 138: 266-271
        • Kalf J.G.
        • de Swart B.J.
        • Bloem B.R.
        • Munneke M.
        Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta-analysis.
        Parkinsonism Related Disord. 2012; 18: 311-315
        • Monteiro L.
        • Souza-Machado A.
        • Pinho P.
        • Sampaio M.
        • Nobrega A.C.
        • Melo A.
        Swallowing impairment and pulmonary dysfunction in Parkinson's disease: the silent threats.
        J Neurol Sci. 2014; 339: 149-152
        • Sutton J.P.
        Dysphagia in Parkinson's disease is responsive to levodopa.
        Parkinsonism Related Disord. 2013; 19: 282-284
        • Monteiro L.
        • Souza-Machado A.
        • Valderramas S.
        • Melo A.
        The effect of levodopa on pulmonary function in Parkinson's disease: a systematic review and meta-analysis.
        Clin Ther. 2012; 34: 1049-1055
        • van Hooren M.R.
        • Baijens L.W.
        • Voskuilen S.
        • Oosterloo M.
        • Kremer B.
        Treatment effects for dysphagia in Parkinson's disease: a systematic review.
        Parkinsonism Related Disord. 2014; 20: 800-807
        • Baijens L.W.
        • Speyer R.
        Effects of therapy for dysphagia in Parkinson's disease: systematic review.
        Dysphagia. 2009; 24: 91-102
        • Skelly R.
        • Brown L.
        • Fakis A.
        • Kimber L.
        • Downes C.
        • Lindop F.
        • Johnson C.
        • Bartliff C.
        • Bajaj N.
        Does a specialist unit improve outcomes for hospitalized patients with Parkinson's disease?.
        Parkinsonism Related Disord. 2014; 20: 1242-1247
        • Ziemssen T.
        • Reichmann H.
        Cardiovascular autonomic dysfunction in Parkinson's disease.
        J Neurol Sci. 2010; 289: 74-80
        • Higuchi Y.
        • Iacono R.P.
        Surgical complications in patients with Parkinson's disease after posteroventral pallidotomy.
        Neurosurgery. 2003; 52 (discussion 568-571): 558-571
        • Johns D.W.
        • Ayers C.R.
        • Carey R.M.
        The dopamine agonist bromocriptine induces hypotension by venous and arteriolar dilation.
        J Cardiovasc Pharmacol. 1984; 6: 582-587
        • Glassman A.H.
        • Bigger Jr., J.T.
        Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review.
        Arch Gen Psychiatry. 1981; 38: 815-820
        • Stollberger C.
        • Huber J.O.
        • Finsterer J.
        Antipsychotic drugs and QT prolongation.
        Int Clin Psychopharmacol. 2005; 20: 243-251
        • Malek N.M.
        • Grosset K.A.
        • Stewart D.
        • Macphee G.J.
        • Grosset D.G.
        Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease.
        Parkinsonism Related Disord. 2013; 19: 586-589
        • Schouten E.G.
        • Dekker J.M.
        • Meppelink P.
        • Kok F.J.
        • Vandenbroucke J.P.
        • Pool J.
        QT interval prolongation predicts cardiovascular mortality in an apparently healthy population.
        Circulation. 1991; 84: 1516-1523
        • Soliman E.Z.
        • Howard G.
        • Cushman M.
        • Kissela B.
        • Kleindorfer D.
        • Le A.
        • Judd S.
        • McClure L.A.
        • Howard V.J.
        Prolongation of QTc and risk of stroke: The REGARDS (REasons for Geographic and Racial Differences in Stroke) study.
        J Am Coll Cardiol. 2012; 59: 1460-1467
        • Zanettini R.
        • Antonini A.
        • Gatto G.
        • Gentile R.
        • Tesei S.
        • Pezzoli G.
        Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
        N Engl J Med. 2007; 356: 39-46
        • Zrinzo L.
        • Foltynie T.
        • Limousin P.
        • Hariz M.I.
        Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review.
        J Neurosurg. 2012; 116: 84-94
        • Barber M.
        • Stewart D.
        • Grosset D.
        • MacPhee G.
        Patient and carer perception of the management of Parkinson's disease after surgery.
        Age Ageing. 2001; 30: 171-172
        • Domingo-Echaburu S.
        • Lertxundi U.
        • Gonzalo-Olazabal E.
        • Peral-Aguirregoitia J.
        • Pena-Bandres I.
        Inappropriate antidopaminergic drug use in Parkinson’s disease inpatients.
        Curr Drug Ther. 2012; 7: 164-169
        • Brennan K.A.
        • Genever R.W.
        Managing Parkinson’s disease during surgery.
        BMJ (Clin Res Ed). 2010; 341: c5718
        • Cunningham D.
        • Evans C.
        • Gazet J.C.
        • Ford H.
        • Pople A.
        • Dearling J.
        • Chappell D.
        • Coombes C.
        Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens.
        BMJ (Clin Res Ed). 1987; 295 (250)
        • Johannes C.B.
        • Varas-Lorenzo C.
        • McQuay L.J.
        • Midkiff K.D.
        • Fife D.
        Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study.
        Pharmacoepidemiol Drug Saf. 2010; 19: 881-888
        • van Noord C.
        • Dieleman J.P.
        • van Herpen G.
        • Verhamme K.
        • Sturkenboom M.C.
        Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands.
        Drug Saf. 2010; 33: 1003-1014
        • Mets B.
        Acute dystonia after alfentanil in untreated Parkinson's disease.
        Anesth Analg. 1991; 72: 557-558
        • Burton D.A.
        • Nicholson G.
        • Hall G.M.
        Anaesthesia in elderly patients with neurodegenerative disorders: special considerations.
        Drugs Aging. 2004; 21: 229-242
        • Henry B.
        • Fox S.H.
        • Crossman A.R.
        • Brotchie J.M.
        μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease.
        Exp Neurol. 2001; 171: 139-146
        • Samadi P.
        • Gregoire L.
        • Bedard P.J.
        Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
        Neuropharmacology. 2003; 45: 954-963
        • Berg D.
        • Becker G.
        • Reiners K.
        Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica.
        J Neural Transm (Vienna, Austria: 1996). 1999; 106: 725-728
        • Liu S.S.
        • Wu C.L.
        Effect of postoperative analgesia on major postoperative complications: a systematic update of the evidence.
        Anesth Analg. 2007; 104: 689-702
        • Hirsch E.C.
        • Hunot S.
        • Damier P.
        • Faucheux B.
        Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?.
        Ann Neurol. 1998; 44: S115-S120
        • Group PS
        A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
        Arch Neurol. 2005; 62: 241-248
        • Knoll J.
        The pharmacology of selegiline ((−)deprenyl). New aspects.
        Acta Neurol Scand Supplementum. 1989; 126: 83-91
        • Lecht S.
        • Haroutiunian S.
        • Hoffman A.
        • Lazarovici P.
        Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy.
        Ther Clin Risk Manag. 2007; 3: 467-474
        • Lees A.J.
        • Kohout L.J.
        • Shaw K.M.
        • Stern G.M.
        • Elsworth J.D.
        • Sandler M.
        • Youdim M.B.H.
        Deprenyl in Parkinson’s disease.
        Lancet. 1977; 310: 791-795
        • Richard I.H.
        • Kurlan R.
        • Tanner C.
        • Factor S.
        • Hubble J.
        • Suchowersky O.
        • Waters C.
        Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.
        Neurology. 1997; 48: 1070-1077
        • Csoti I.
        • Storch A.
        • Müller W.
        • Jost W.H.
        Drug interactions with selegiline versus rasagiline.
        Basal Ganglia. 2012; 2: S27-S31
        • Heinonen E.H.
        • Lammintausta R.
        A review of the pharmacology of selegiline.
        Acta Neurol Scand Supplementum. 1991; 136: 44-59
        • Volpi-Abadie J.
        • Kaye A.M.
        • Kaye A.D.
        Serotonin syndrome.
        Ochsner J. 2013; 13: 533-540
        • Fernandes C.
        • Reddy P.
        • Kessel B.
        Rasagiline-induced serotonin syndrome.
        Mov Disord. 2011; 26: 766-767
        • Rogers K.J.
        • Thornton J.A.
        The interaction between monoamine oxidase inhibitors and narcotic analgesics in mice.
        Br J Pharmacol. 1969; 36: 470-480
        • Aarsland D.
        • Pahlhagen S.
        • Ballard C.G.
        • Ehrt U.
        • Svenningsson P.
        Depression in Parkinson disease–epidemiology, mechanisms and management.
        Nat Rev Neurol. 2012; 8: 35-47
        • Reed A.P.
        • Han D.G.
        Intraoperative exacerbation of Parkinson's disease.
        Anesth Analg. 1992; 75: 850-853
        • Stagg P.
        • Grice T.
        Nasogastric medication for perioperative Parkinson's rigidity during anaesthesia emergence.
        Anaesth Intensive Care. 2011; 39: 1128-1130
      3. Australian and New Zealand College of Anaesthetists. Recommendations for the perioperative care of patients selected for day care surgery PS15, http://www.anzca.edu.au/resources/professional-documents/pdfs/ps15-2010-recommendations-for-the-perioperative-care-of-patients-selected-for-day-care-surgery.pdf; 2010.

        • Contin M.
        • Riva R.
        • Martinelli P.
        • Albani F.
        • Baruzzi A.
        Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.
        Eur J Clin Pharmacol. 1991; 41: 463-466
        • Dotson R.G.
        • Robinson R.G.
        • Pingleton S.K.
        Gastroesophageal reflux with nasogastric tubes. Effect of nasogastric tube size.
        Am J Resp Crit Care Med. 1994; 149: 1659-1662
        • Factor S.A.
        Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
        Neurology. 2004; 62: S12-S17
        • Galvez-Jimenez N.
        • Lang A.E.
        Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone.
        Can J Neurol Sci Le journal canadien des sciences neurologiques. 1996; 23: 198-203
        • Deleu D.
        • Hanssens Y.
        • Northway M.G.
        Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease.
        Drugs Aging. 2004; 21: 687-709
        • Wüllner U.
        • Kassubek J.
        • Odin P.
        • Schwarz M.
        • Naumann M.
        • Häck H.-J.
        • Boroojerdi B.
        • Reichmann H.
        Transdermal rotigotine for the perioperative management of Parkinson’s disease.
        J Neural Transm. 2010; 117: 855-859
        • Wood B.H.
        • Bilclough J.A.
        • Bowron A.
        • Walker R.W.
        Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study.
        J Neurol Neurosurg Psychiatry. 2002; 72: 721-725
        • Bushmann M.
        • Dobmeyer S.M.
        • Leeker L.
        • Perlmutter J.S.
        Swallowing abnormalities and their response to treatment in Parkinson's disease.
        Neurology. 1989; 39: 1309-1314
        • Magdalinou K.N.
        • Martin A.
        • Kessel B.
        Prescribing medications in Parkinson's disease (PD) patients during acute admissions to a District General Hospital.
        Parkinsonism Related Disord. 2007; 13: 539-540
        • Aminoff M.J.
        • Christine C.W.
        • Friedman J.H.
        • Chou K.L.
        • Lyons K.E.
        • Pahwa R.
        • Bloem B.R.
        • Parashos S.A.
        • Price C.C.
        • Malaty I.A.
        • Iansek R.
        • Bodis-Wollner I.
        • Suchowersky O.
        • Oertel W.H.
        • Zamudio J.
        • Oberdorf J.
        • Schmidt P.
        • Okun M.S.
        Management of the hospitalized patient with Parkinson’s disease: Current state of the field and need for guidelines.
        Parkinsonism Related Disord. 2011; 17: 139-145
        • Gerlach O.H.
        • Rouvroije V.J.
        • Weber W.E.
        Parkinson's disease and hospitalization: the need for guidelines.
        Parkinsonism Related Disord. 2011; 17: 498
        • Holland J.
        Care of patients with Parkinson's disease in the operating department.
        J Perioperative Pract. 2010; 20: 406-410
        • Diltoer M.W.
        • Rosseneu S.
        • Ramet J.
        • De Wolf D.
        • Spapen H.D.
        • De Turck B.J.
        • Huyghens L.P.
        Anticholinergic treatment for choreoathetosis in a child after induction with propofol.
        Anesth Analg. 1996; 82: 670
        • Antkowiak B.
        Different actions of general anesthetics on the firing patterns of neocortical neurons mediated by the GABA(A) receptor.
        Anesthesiology. 1999; 91: 500-511
        • Calon F.
        • Di Paolo T.
        Levodopa response motor complications–GABA receptors and preproenkephalin expression in human brain.
        Parkinsonism Related Disord. 2002; 8: 449-454
        • Deogaonkar A.
        • Deogaonkar M.
        • Lee J.Y.
        • Ebrahim Z.
        • Schubert A.
        Propofol-induced dyskinesias controlled with dexmedetomidine during deep brain stimulation surgery.
        Anesthesiology. 2006; 104: 1337-1339
        • Raz A.
        • Eimerl D.
        • Zaidel A.
        • Bergman H.
        • Israel Z.
        Propofol decreases neuronal population spiking activity in the subthalamic nucleus of Parkinsonian patients.
        Anesth Analg. 2010; 111: 1285-1289
        • Albin R.L.
        • Young A.B.
        • Penney J.B.
        The functional anatomy of basal ganglia disorders.
        Trends Neurosci. 1989; 12: 366-375
        • Krauss J.K.
        • Borremans J.J.
        • Nobbe F.
        • Mundinger F.
        Ballism not related to vascular disease: A report of 16 patients and review of the literature.
        Parkinsonism Related Disord. 1996; 2: 35-45
        • Kalenka A.
        • Schwarz A.
        Anaesthesia and Parkinson's disease: how to manage with new therapies?.
        Curr Opin Anaesthesiol. 2009; 22: 419-424
        • Opacka-Juffry J.
        • Ahier R.G.
        • Cremer J.E.
        Nomifensine-induced increase in extracellular striatal dopamine is enhanced by isoflurane anaesthesia.
        Synapse (New York, NY). 1991; 7: 169-171
        • el-Maghrabi E.A.
        • Eckenhoff R.G.
        Inhibition of dopamine transport in rat brain synaptosomes by volatile anesthetics.
        Anesthesiology. 1993; 78: 750-756
        • Irifune M.
        • Sato T.
        • Nishikawa T.
        • Masuyama T.
        • Nomoto M.
        • Fukuda T.
        • Kawahara M.
        Hyperlocomotion during recovery from isoflurane anesthesia is associated with increased dopamine turnover in the nucleus accumbens and striatum in mice.
        Anesthesiology. 1997; 86: 464-475
        • Goldberg L.I.
        • Whitsett T.L.
        Cardiovascular effects of levodopa.
        JAMA. 1971; 218: 1921-1923
        • Parks L.C.
        • Watanabe A.M.
        • Kopin I.J.
        Prevention or reversal of levodopa-induced cardiac arrhythmias by decarboxylase inhibitors.
        Lancet. 1970; 2: 1014-1015
        • Jevtovic-Todorovic V.
        • Hartman R.E.
        • Izumi Y.
        • Benshoff N.D.
        • Dikranian K.
        • Zorumski C.F.
        • Olney J.W.
        • Wozniak D.F.
        Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits.
        J Neurosci. 2003; 23: 876-882
        • Paule M.G.
        • Li M.
        • Allen R.R.
        • Liu F.
        • Zou X.
        • Hotchkiss C.
        • Hanig J.P.
        • Patterson T.A.
        • Slikker Jr., W.
        • Wang C.
        Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys.
        Neurotoxicol Teratol. 2011; 33: 220-230
        • Pesic V.
        • Milanovic D.
        • Tanic N.
        • Popic J.
        • Kanazir S.
        • Jevtovic-Todorovic V.
        • Ruzdijic S.
        Potential mechanism of cell death in the developing rat brain induced by propofol anesthesia.
        Int J Dev Neurosci. 2009; 27: 279-287
        • Prozesky J.
        Anaesthesia and the developing brain.
        South Afr J Anaesth Analgesia. 2014; 20: 167-169
        • Sun L.
        Early childhood general anaesthesia exposure and neurocognitive development.
        Br J Anaesth. 2010; 105: i61-i68
        • Yon J.H.
        • Daniel-Johnson J.
        • Carter L.B.
        • Jevtovic-Todorovic V.
        Anesthesia induces neuronal cell death in the developing rat brain via the intrinsic and extrinsic apoptotic pathways.
        Neuroscience. 2005; 135: 815-827
        • Zhou Z.W.
        • Shu Y.
        • Li M.
        • Guo X.
        • Pac-Soo C.
        • Maze M.
        • Ma D.
        The glutaminergic, GABAergic, dopaminergic but not cholinergic neurons are susceptible to anaesthesia-induced cell death in the rat developing brain.
        Neuroscience. 2011; 174: 64-70
        • Gleich S.J.
        • Flick R.
        • Hu D.
        • Zaccariello M.J.
        • Colligan R.C.
        • Katusic S.K.
        • Schroeder D.R.
        • Hanson A.
        • Buenvenida S.
        • Wilder R.T.
        • Sprung J.
        • Voigt R.G.
        • Paule M.G.
        • Chelonis J.J.
        • Warner D.O.
        Neurodevelopment of children exposed to anesthesia: design of the Mayo Anesthesia Safety in Kids (MASK) study.
        Contemporary Clin Trials. 2015; 41: 45-54
        • Ing C.
        • DiMaggio C.
        • Whitehouse A.
        • Hegarty M.K.
        • Brady J.
        • von Ungern-Sternberg B.S.
        • Davidson A.
        • Wood A.J.
        • Li G.
        • Sun L.S.
        Long-term differences in language and cognitive function after childhood exposure to anesthesia.
        Pediatrics. 2012; 130: e476-e485
        • Wilder R.T.
        • Flick R.P.
        • Sprung J.
        • Katusic S.K.
        • Barbaresi W.J.
        • Mickelson C.
        • Gleich S.J.
        • Schroeder D.R.
        • Weaver A.L.
        • Warner D.O.
        Early exposure to anesthesia and learning disabilities in a population-based birth cohort.
        Anesthesiology. 2009; 110: 796-804
        • Jevtovic-Todorovic V.
        • Absalom A.R.
        • Blomgren K.
        • Brambrink A.
        • Crosby G.
        • Culley D.J.
        • Fiskum G.
        • Giffard R.G.
        • Herold K.F.
        • Loepke A.W.
        • Ma D.
        • Orser B.A.
        • Planel E.
        • Slikker Jr., W.
        • Soriano S.G.
        • Stratmann G.
        • Vutskits L.
        • Xie Z.
        • Hemmings Jr., H.C.
        Anaesthetic neurotoxicity and neuroplasticity: an expert group report and statement based on the BJA Salzburg Seminar.
        Br J Anaesth. 2013; 111: 143-151
        • Hays S.R.
        • Deshpande J.K.
        Newly postulated neurodevelopmental risks of pediatric anesthesia: theories that could rock our world.
        J Urol. 2013; 189: 1222-1228
        • Mastrangelo G.
        • Comiati V.
        • dell’Aquila M.
        • Zamprogno E.
        Exposure to anesthetic gases and Parkinson’s disease: a case report.
        BMC Neurol. 2013; 13 (194)
        • Peretz C.
        • Alexander B.H.
        • Nagahama S.I.
        • Domino K.B.
        • Checkoway H.
        Parkinson's disease mortality among male anesthesiologists and internists.
        Mov Disord. 2005; 20: 1614-1617
        • Zorzon M.
        • Capus L.
        • Pellegrino A.
        • Cazzato G.
        • Zivadinov R.
        Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy.
        Acta Neurol Scand. 2002; 105: 77-82
        • Mogenson G.J.
        • Jones D.L.
        • Yim C.Y.
        From motivation to action: functional interface between the limbic system and the motor system.
        Prog Neurobiol. 1980; 14: 69-97
        • Zhu C.
        • Gao J.
        • Karlsson N.
        • Li Q.
        • Zhang Y.
        • Huang Z.
        • Li H.
        • Kuhn H.G.
        • Blomgren K.
        Isoflurane anesthesia induced persistent, progressive memory impairment, caused a loss of neural stem cells, and reduced neurogenesis in young, but not adult, rodents.
        J Cerebral Blood Flow Metabol. 2010; 30: 1017-1030
        • Zhao M.
        • Momma S.
        • Delfani K.
        • Carlen M.
        • Cassidy R.M.
        • Johansson C.B.
        • Brismar H.
        • Shupliakov O.
        • Frisen J.
        • Janson A.M.
        Evidence for neurogenesis in the adult mammalian substantia nigra.
        Proc Natl Acad Sci USA. 2003; 100: 7925-7930
        • Shan X.
        • Chi L.
        • Bishop M.
        • Luo C.
        • Lien L.
        • Zhang Z.
        • Liu R.
        Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice.
        Stem Cells (Dayton, Ohio). 2006; 24: 1280-1287
        • Wirdefeldt K.
        • Adami H.O.
        • Cole P.
        • Trichopoulos D.
        • Mandel J.
        Epidemiology and etiology of Parkinson's disease: a review of the evidence.
        Eur J Epidemiol. 2011; 26: S1-S58
        • Schrag A.
        • Schott J.M.
        Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism.
        Lancet Neurol. 2006; 5: 355-363